Change in Alzheimer's Disease Blood-Based Biomarkers and Brain Amyloid Deposition
Author Information
Author(s): Pike James, Lu Yifei, Chen Jinyu, Walker Keenan, Sullivan Kevin, Griswold Michael, Mosley Thomas, Palta Priya
Hypothesis
Do blood-based biomarkers measured in midlife and late-life correlate with amyloid positivity in late-life?
Conclusion
Late-life measurements of certain blood-based biomarkers are associated with a higher likelihood of amyloid positivity in older adults.
Supporting Evidence
- Blood-based biomarkers can be a noninvasive method for measuring Alzheimer's disease pathology.
- The study found that late-life measurements of certain biomarkers were associated with amyloid positivity.
- The greatest accuracy in predicting amyloid positivity was achieved using all assays from both midlife and late-life.
Takeaway
Scientists are studying blood tests to see if they can help predict Alzheimer's disease by looking at changes in the blood over time.
Methodology
Participants underwent brain MRI and PET scans, and blood samples were analyzed for specific biomarkers.
Limitations
The study only included dementia-free participants and may not represent all populations.
Participant Demographics
Dementia-free participants from diverse, community-dwelling populations, with a mean age of 58.5 years in midlife and 76.2 years in late-life.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website